CA2824092C - Use of alk inhibitors for the treatment of eml4-alk+ non-small cell lung cancer - Google Patents
Use of alk inhibitors for the treatment of eml4-alk+ non-small cell lung cancer Download PDFInfo
- Publication number
- CA2824092C CA2824092C CA2824092A CA2824092A CA2824092C CA 2824092 C CA2824092 C CA 2824092C CA 2824092 A CA2824092 A CA 2824092A CA 2824092 A CA2824092 A CA 2824092A CA 2824092 C CA2824092 C CA 2824092C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- phenyl
- alk
- eml4
- lung cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161438878P | 2011-02-02 | 2011-02-02 | |
| US61/438,878 | 2011-02-02 | ||
| PCT/US2012/023669 WO2012106540A1 (en) | 2011-02-02 | 2012-02-02 | Methods of using alk inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2824092A1 CA2824092A1 (en) | 2012-08-09 |
| CA2824092C true CA2824092C (en) | 2020-06-30 |
Family
ID=45582065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2824092A Active CA2824092C (en) | 2011-02-02 | 2012-02-02 | Use of alk inhibitors for the treatment of eml4-alk+ non-small cell lung cancer |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8703787B2 (enExample) |
| EP (1) | EP2670401B1 (enExample) |
| JP (1) | JP5837095B2 (enExample) |
| KR (1) | KR101521861B1 (enExample) |
| CN (1) | CN103458881B (enExample) |
| AU (1) | AU2012212142B2 (enExample) |
| BR (1) | BR112013019643B1 (enExample) |
| CA (1) | CA2824092C (enExample) |
| CY (1) | CY1116662T1 (enExample) |
| DK (1) | DK2670401T3 (enExample) |
| EA (1) | EA023404B1 (enExample) |
| ES (1) | ES2543567T3 (enExample) |
| HR (1) | HRP20150946T1 (enExample) |
| HU (1) | HUE025395T2 (enExample) |
| ME (1) | ME02200B (enExample) |
| MX (1) | MX2013008791A (enExample) |
| PL (1) | PL2670401T3 (enExample) |
| PT (1) | PT2670401E (enExample) |
| RS (1) | RS54189B1 (enExample) |
| SI (1) | SI2670401T1 (enExample) |
| SM (1) | SMT201500300B (enExample) |
| WO (1) | WO2012106540A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104854101B (zh) | 2012-11-06 | 2018-05-01 | 上海复尚慧创医药研究有限公司 | Alk激酶抑制剂 |
| AU2013341271A1 (en) * | 2012-11-07 | 2015-05-14 | Novartis Ag | Combination therapy |
| CN104109149B (zh) * | 2013-04-22 | 2018-09-28 | 苏州泽璟生物制药有限公司 | 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物 |
| ITMI20131124A1 (it) * | 2013-07-04 | 2015-01-05 | Univ Milano Bicocca | 2-acilamminotiazoli per il trattamento del cancro |
| JP6510510B2 (ja) * | 2013-07-11 | 2019-05-08 | ベータ ファーマシューティカルズ カンパニー リミテッド | プロテインチロシンキナーゼモジュレーター及び使用方法 |
| US20160361314A1 (en) * | 2013-08-28 | 2016-12-15 | Novartis Ag | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases |
| CN104672214B (zh) * | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| AU2014372166B2 (en) * | 2013-12-23 | 2017-10-26 | Novartis Ag | Pharmaceutical combinations |
| KR101656382B1 (ko) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
| CN104876914B (zh) * | 2014-02-28 | 2017-04-19 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
| US10053458B2 (en) * | 2014-06-17 | 2018-08-21 | Korea Research Institute Of Chemical Technology | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
| CN105524045B (zh) * | 2014-10-22 | 2020-04-10 | 山东轩竹医药科技有限公司 | 四环类间变性淋巴瘤激酶抑制剂 |
| CN106146525B (zh) * | 2015-04-10 | 2018-11-02 | 山东轩竹医药科技有限公司 | 三并环类间变性淋巴瘤激酶抑制剂 |
| CN106220644B (zh) | 2015-04-24 | 2020-07-31 | 广州再极医药科技有限公司 | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 |
| CN106699743B (zh) | 2015-11-05 | 2020-06-12 | 湖北生物医药产业技术研究院有限公司 | 嘧啶类衍生物及其用途 |
| CN106220608B (zh) * | 2016-07-25 | 2018-11-27 | 安润医药科技（苏州）有限公司 | 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途 |
| CN107698603B (zh) * | 2016-08-09 | 2022-04-08 | 南京红云生物科技有限公司 | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 |
| SG11201901251SA (en) * | 2016-08-29 | 2019-03-28 | Univ Michigan Regents | Aminopyrimidines as alk inhibitors |
| CN111484484B (zh) * | 2020-04-13 | 2021-11-23 | 沈阳药科大学 | 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| ATE542801T1 (de) * | 2003-08-15 | 2012-02-15 | Novartis Ag | Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| WO2008007368A2 (en) | 2006-07-10 | 2008-01-17 | Rf Dynamics Ltd. | Food preparation |
| CA2598893C (en) * | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| JP5208123B2 (ja) * | 2006-12-08 | 2013-06-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| EA019941B1 (ru) * | 2006-12-08 | 2014-07-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| AU2009233964B2 (en) * | 2008-04-07 | 2012-06-07 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
-
2012
- 2012-02-02 PT PT127036705T patent/PT2670401E/pt unknown
- 2012-02-02 EA EA201391114A patent/EA023404B1/ru not_active IP Right Cessation
- 2012-02-02 KR KR1020137023001A patent/KR101521861B1/ko active Active
- 2012-02-02 CA CA2824092A patent/CA2824092C/en active Active
- 2012-02-02 PL PL12703670T patent/PL2670401T3/pl unknown
- 2012-02-02 HR HRP20150946TT patent/HRP20150946T1/hr unknown
- 2012-02-02 US US13/981,046 patent/US8703787B2/en active Active
- 2012-02-02 AU AU2012212142A patent/AU2012212142B2/en active Active
- 2012-02-02 CN CN201280007465.9A patent/CN103458881B/zh active Active
- 2012-02-02 JP JP2013552637A patent/JP5837095B2/ja active Active
- 2012-02-02 ME MEP-2015-127A patent/ME02200B/me unknown
- 2012-02-02 BR BR112013019643-2A patent/BR112013019643B1/pt active IP Right Grant
- 2012-02-02 SI SI201230285T patent/SI2670401T1/sl unknown
- 2012-02-02 RS RS20150563A patent/RS54189B1/sr unknown
- 2012-02-02 HU HUE12703670A patent/HUE025395T2/en unknown
- 2012-02-02 EP EP12703670.5A patent/EP2670401B1/en active Active
- 2012-02-02 MX MX2013008791A patent/MX2013008791A/es unknown
- 2012-02-02 WO PCT/US2012/023669 patent/WO2012106540A1/en not_active Ceased
- 2012-02-02 DK DK12703670.5T patent/DK2670401T3/en active
- 2012-02-02 ES ES12703670.5T patent/ES2543567T3/es active Active
-
2015
- 2015-08-28 CY CY20151100758T patent/CY1116662T1/el unknown
- 2015-11-30 SM SM201500300T patent/SMT201500300B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201391114A1 (ru) | 2013-12-30 |
| AU2012212142A1 (en) | 2013-08-15 |
| ME02200B (me) | 2016-02-20 |
| JP2014504646A (ja) | 2014-02-24 |
| CA2824092A1 (en) | 2012-08-09 |
| DK2670401T3 (en) | 2015-09-07 |
| EP2670401B1 (en) | 2015-06-10 |
| KR20130121174A (ko) | 2013-11-05 |
| JP5837095B2 (ja) | 2015-12-24 |
| HUE025395T2 (en) | 2016-02-29 |
| US20130296357A1 (en) | 2013-11-07 |
| CN103458881B (zh) | 2015-08-12 |
| BR112013019643B1 (pt) | 2022-04-19 |
| CN103458881A (zh) | 2013-12-18 |
| WO2012106540A1 (en) | 2012-08-09 |
| AU2012212142B2 (en) | 2015-09-24 |
| RS54189B1 (sr) | 2015-12-31 |
| SMT201500300B (it) | 2016-01-08 |
| PT2670401E (pt) | 2015-10-12 |
| BR112013019643A2 (pt) | 2016-10-04 |
| PL2670401T3 (pl) | 2015-11-30 |
| SI2670401T1 (sl) | 2015-10-30 |
| HRP20150946T1 (hr) | 2015-10-09 |
| MX2013008791A (es) | 2013-10-07 |
| EA023404B1 (ru) | 2016-05-31 |
| CY1116662T1 (el) | 2017-03-15 |
| US8703787B2 (en) | 2014-04-22 |
| EP2670401A1 (en) | 2013-12-11 |
| KR101521861B1 (ko) | 2015-05-21 |
| ES2543567T3 (es) | 2015-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012212142B2 (en) | Methods of using ALK inhibitors | |
| US11478469B2 (en) | Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases | |
| TWI389893B (zh) | 二（芳胺基）芳基化合物 | |
| US20150202203A1 (en) | Method of Treating Gastrointestinal Stromal Tumors | |
| TWI759316B (zh) | Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物 | |
| ES2930106T3 (es) | Compuesto derivado de pirrol-piridina, procedimiento para preparar el mismo y composición farmacéutica que contiene el mismo como ingrediente activo para la prevención o el tratamiento de enfermedades relacionadas con la proteína quinasa | |
| KR20190110581A (ko) | 암 치료 | |
| JP2023553532A (ja) | 癌の処置のための併用療法 | |
| CN118338905A (zh) | Wee1激酶抑制剂在治疗癌症中的应用 | |
| JP2024125139A (ja) | アズブジンを含む抗腫瘍医薬組成物 | |
| KR20210126654A (ko) | 암 치료 | |
| US20240197737A1 (en) | Application of compound in preparation of inhibitory drug targeting erbb2 mutant | |
| US20250339412A1 (en) | Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine | |
| CN103638028A (zh) | 嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用 | |
| Jasim et al. | A comprehensive review of immunotherapy in gastrointestinal tumors with a focus on the role of combination therapy with PARP inhibitors | |
| CN113840823B (zh) | 显示癌细胞生长抑制效果的新型杂环取代的嘧啶衍生物，以及包含其的药物组合物 | |
| WO2017090699A1 (ja) | ピラジンカルボキサミド化合物を有効成分とするがん免疫治療用医薬組成物、及び／又は、免疫活性化用医薬組成物 | |
| TW202140005A (zh) | 用於治療發炎疾病之新穎藥物 | |
| CN110664811A (zh) | 阿法替尼在抗结核分枝杆菌药物中的应用 | |
| HK40007956A (en) | Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170123 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241205 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241205 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241205 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260120 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260120 |